Last reviewed · How we verify
NCT06227611
Evaluation of Different Perimetric Grids to Detect Central Visual Field Defect in Glaucoma Patients with Reduce Ganglion Cell Layer Thickness Measured by Spectral Domain OCT.
trial in Glaucoma in 16 participants. Currently enrolling.
4 May 2022
Quick facts
| Lead sponsor | Fondazione G.B. Bietti, IRCCS |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 16 |
| Start date | 4 May 2021 |
| Primary completion | 4 May 2022 |
| Estimated completion | 4 May 2025 |
| Sites | 2 locations across Italy |
Conditions studied
- Glaucoma — all drugs for Glaucoma →
Sponsor
Fondazione G.B. Bietti, IRCCS — full company profile →
Who can join
18 and older, any sex, with Glaucoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to evaluate the agreement between three different grids in detecting central visual field defect in early glaucoma patients with reduced ganglion cell layer thickness.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06227611
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glaucoma
Currently open trials in the same condition.
- NCT07455786 — Modified Trabeculectomy After Failure of Combined Phaco With GATT · NA · recruiting
- NCT07298356 — Automated Applanation Tonometry - Updated · NA · recruiting
- NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
- NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies · NA · recruiting
- NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro · Phase 4 · recruiting
Other Fondazione G.B. Bietti, IRCCS trials
Trials by the same sponsor.
- NCT06906003 — Visual Rehabilitation and Depression in Visually Impaired Patients with AMD · recruiting
- NCT05976139 — Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies · NA · recruiting
- NCT06278597 — Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device · NA · completed
- NCT05299593 — 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or O · Phase 4 · unknown
- NCT03598205 — Curcumin and Intravitreal Dexamethasone in Diabetic Macular Edema · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06227611 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione G.B. Bietti, IRCCS
- Last refreshed: 27 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06227611.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing